The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing ...
Pharmaceutical Technology on MSN2d
Macau approves IASO Bio’s multiple myeloma therapyPharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new drug application (NDA) for equecabtagene ...
A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...
For higher-risk multiple myeloma (MM), successful patient selection and monitoring strategies are vital for the management of adverse events and the disease itself.
Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.
Triplet therapy with bortezomib, lenalidomide and dexamethasone — a regimen often referred to as VRd — is a current standard ...
A panel of experts discussed the transition of care between community and academic centers at the CURE Educated Patient ...
The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback